deltatrials
Completed PHASE3 INTERVENTIONAL 4-arm NCT02607930

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Sponsor: Gilead Sciences

Conditions HIV-1 Infection
Interventions ABC/DTG/3TC ABC/DTG/3TC Placebo B/F/TAF B/F/TAF Placebo
Updated 19 times since 2017 Last updated: Feb 7, 2022 Started: Nov 13, 2015 Primary completion: May 9, 2017 Completion: Jul 2, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates HIV-1 Infection and is currently completed. Gilead Sciences leads this study, which shows 19 recorded versions since 2015 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Dec 2017 · 6 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Jan 2019 · 4 months · monthly snapshot~Jan 2019 – ~Jun 2019 · 5 months · monthly snapshot~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshot~Aug 2019 – ~Feb 2020 · 6 months · monthly snapshot~Feb 2020 – ~May 2020 · 3 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE3

  5. Sep 2021 — Apr 2022 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

▶ Show 14 earlier versions

  1. Feb 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

  2. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE3

  3. May 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  4. Feb 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE3

  5. Aug 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE3

  6. Jun 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE3

  7. Jan 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE3

  8. Sep 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE3

  9. Aug 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE3

  10. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE3

  11. Dec 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  12. Jun 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE3

  13. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE3

  14. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Nov 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gilead Sciences
Data source: Gilead Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Albany, United States , Alicante, Spain , Atlanta, United States , Augusta, United States , Austin, United States , Badalona, Spain , Barcelona, Spain , Bellaire, United States , Bergamo, Italy and 79 more locations